Biotech Consulting

Financial Modeling — rNPV

An interactive risk-adjusted net present value model. Adjust the parameters or edit any cell to recalculate the program valuation.

Kyverna single-program rNPV. Edit any blue cell to recalculate. Cumulative PoS carries within a phase and multiplies at each phase transition.

PhasePhase 2Phase 3Commercial PhaseTerminal Year
Year ($M)2026202720282029203020312032203320342035203620372038203920402041204220432044
US gross revenue
Gross to net (GTN) discount
US net revenue$0.0M$0.0M$0.0M$0.0M$0.0M$659.1M$1,318.2M$1,977.3M$2,636.4M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M$3,295.5M
ex-US revenue
COGS
Gross Profit$0.0M$0.0M$0.0M$0.0M$0.0M$253.5M$507.0M$760.5M$1,622.4M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M$2,028.0M
R&D
SG&A
EBIT-$35.0M-$35.0M-$105.0M-$105.0M-$140.0M-$233.2M-$365.0M-$395.5M$283.9M$354.9M$354.9M$354.9M$354.9M$354.9M$354.9M$354.9M$354.9M$354.9M$354.9M
Probability of Success (PoS)
Cumulative PoS1.00001.00000.35000.35000.22750.20480.20480.20480.20480.20480.20480.20480.20480.20480.20480.20480.20480.20480.2048
rNPV-$35.0M-$35.0M-$36.8M-$36.8M-$31.8M-$47.8M-$74.7M-$81.0M$58.1M$72.7M$72.7M$72.7M$72.7M$72.7M$72.7M$72.7M$72.7M$72.7M$72.7M
Discounted rNPV-$35.0M-$31.5M-$29.8M-$26.9M-$21.0M-$28.3M-$40.0M-$39.0M$25.2M$28.4M$25.6M$23.1M$20.8M$18.7M$16.9M$15.2M$13.7M$12.3M$11.1M
Total rNPV (sum of discounted)-$40.6M
NOVUNDAScience Center

Mentorship that turns curiosity into discovery — the first step toward a future in biotech innovation.

© 2026 Novunda Science Center. All rights reserved.

San Francisco Bay Area